1. 1110. AZD7442 (Tixagevimab/Cilgavimab) Demonstrates Potent In Vitro Activity Against SARS-CoV-2 Spike Variants Identified in Circulation and in Prophylaxis Clinical Studies. (15th December 2022) Authors: Tuffy, Kevin M; Abram, Michael E; Roe, Tiffany L; Ahani, Bahar; Brady, Tyler; Schuko, Nicolette; Clarke, Lori; Caceres, Carolina; Kenny, Tara; Takahashi, Virginia; Zhang, Tianhui; Tabor, David E; Kijak, Gustavo H; Kelly, Elizabeth J; Streicher, Katie Journal: Open forum infectious diseases Issue: Volume 9:(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1160. Treatment-Emergent Viral Variants in the Phase 3 TACKLE Trial Investigating Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for the Treatment of Mild to Moderate COVID-19 in Adults. (15th December 2022) Authors: Kijak, Gustavo H; Ahani, Bahar; Arbetter, Douglas; Brady, Tyler; Chuecos, Fernando; Gopalakrishnan, Vancheswaran; Roe, Tiffany L; Schuko, Nicolette; Richard Hobbs, F D; Padilla, Francisco; Kelly, Elizabeth J; Montgomery, Hugh; Streicher, Katie Journal: Open forum infectious diseases Issue: Volume 9:(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗